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1 ADH = atypical ductal hyperplasia; DCIS = ductal carcinoma in situ; LOH = loss of heterozygosity.
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I read with interest the series of articles on ‘Pre-invasive
breast disease’ in the September and November issues of
Breast Cancer Research [1–9]. Although each of the arti-
cles is well written, the series raises several issues and in
places is contradictory.
Loss of heterozygosity (LOH) has been detected in inva-
sive carcinomas, in ductal carcinoma in situ (DCIS), in
atypical ductal hyperplasia (ADH) and in atypical lobular
hyperplasia/lobular carcinoma in situ [10,11]. LOH has
also been detected in much lesser frequency in ductal
hyperplasia usual type, in normal breast [12] and in
gynecomastia [13].
Two mutually contradictory conclusions can be drawn
from this data. First, LOH studies indicate a progressive
build-up of molecular abnormalities, which in some
instances culminate in malignant transformation. Similar
frequencies of LOH in ADH and in low-grade DCIS indi-
cate a relationship close enough to justify merger of these
entities (suggested by Pinder and Ellis [2]).
The second conclusion is that, since LOH is seen even in
normal breast, it has no significance. This conclusion is
supported by the distinct keratin profiles of ductal hyper-
plasia usual type and of ADH/DCIS [14]. Lesions called
‘atypical hyperplasia’ are either hyperplastic or neoplastic
but are not precursory in nature, and the term ADH is best
discarded (suggested by van de Vijver and Peterse [5]).
The morphological identification and distinction of ADH
from DCIS is problematic to say the least. One can easily
agree with van de Vijver and Peterse [5] in questioning the
use of the term ADH for lesions that have the morphologi-
cal features of DCIS but are smaller than 2mm. Whatever
our individual bias may be, it seems clear from the studies
initiated by Page and colleagues [15] that there exists a
lesion that is a marker of increased risk for breast cancer.
This lesion is similar to atypical lobular hyperplasia/lobular
carcinoma in situ and is distinct from DCIS in that cancers
arising in patients with this lesion are not localized to the
area of prior abnormality, but can arise anywhere in the
same breast or in the contralateral breast. Although some
forms of low-grade DCIS, such as micropapillary DCIS,
can be multicentric, most DCIS is unicentric and cancers
arising in patients with this condition seem to arise at the
site of prior lesion. Whatever the molecular resemblance,
this biologic behavior should be sufficient to merit the dis-
tinction of ADH from DCIS.
I agree that the term ADH is a misnomer as the lesion
arises in terminal duct lobular units and not in ‘true’ ducts
[15]. However, ADH still serves an important function of
identifying a unique lesion that indicates an increase in risk
for breast cancer and indicates that this risk, unlike that
associated with DCIS, is bilateral. Combining ADH with
low-grade DCIS, on the basis of the limited molecular data
currently available, is premature.
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